Global Markets Direct’s, 'Nonhematologic Malignancy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nonhematologic Malignancy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nonhematologic Malignancy. Nonhematologic Malignancy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Nonhematologic Malignancy. - A review of the Nonhematologic Malignancy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Nonhematologic Malignancy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Nonhematologic Malignancy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Nonhematologic Malignancy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Nonhematologic Malignancy - Pipeline Review, H1 2013 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Nonhematologic Malignancy Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Nonhematologic Malignancy 7 Nonhematologic Malignancy Therapeutics under Development by Companies 9 Early Clinical Stage Products 10 Comparative Analysis 10 Nonhematologic Malignancy Therapeutics - Products under Development by Companies 11 Companies Involved in Nonhematologic Malignancy Therapeutics Development 12 Boehringer Ingelheim GmbH 12 Millennium Pharmaceuticals, Inc. 13 Astellas Pharma Inc. 14 Celgene Corporation 15 Cytheris SA 16 Nonhematologic Malignancy - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Drug Profiles 22 pevonedistat - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 sirolimus albumin-bound - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 CYT-99 007 - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 VS-6063 - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 TAK-733 - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 BI-853520 - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 ASP-9853 - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 Nonhematologic Malignancy Therapeutics - Drug Profile Updates 30 Nonhematologic Malignancy Therapeutics - Discontinued Products 32 Nonhematologic Malignancy Therapeutics - Dormant Products 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables
Number of Products Under Development for Nonhematologic Malignancy, H1 2013 7 Products under Development for Nonhematologic Malignancy - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Comparative Analysis by Early Clinical Stage Development, H1 2013 10 Products under Development by Companies, H1 2013 11 Boehringer Ingelheim GmbH, H1 2013 12 Millennium Pharmaceuticals, Inc., H1 2013 13 Astellas Pharma Inc., H1 2013 14 Celgene Corporation, H1 2013 15 Cytheris SA, H1 2013 16 Assessment by Monotherapy Products, H1 2013 17 Assessment by Stage and Route of Administration, H1 2013 19 Assessment by Stage and Molecule Type, H1 2013 21 Nonhematologic Malignancy Therapeutics - Drug Profile Updates 30 Nonhematologic Malignancy Therapeutics - Discontinued Products 32 Nonhematologic Malignancy Therapeutics - Dormant Products 33
List of Figures
Number of Products under Development for Nonhematologic Malignancy, H1 2013 7 Products under Development for Nonhematologic Malignancy - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Early Clinical Stage Products, H1 2013 10 Assessment by Monotherapy Products, H1 2013 17 Assessment by Route of Administration, H1 2013 18 Assessment by Stage and Route of Administration, H1 2013 19 Assessment by Molecule Type, H1 2013 20 Assessment by Stage and Molecule Type, H1 2013 21